



Abstracts from the HTAi 2022 Meeting in Utrecht,
Netherlands

International Journal of

Technology Assessment in Health Care



International Journal of Technology Assessment in Health Care

Official Journal of Health Technology Assessment International

Editor-in-Chief

Wendy Babidge, BApp Sci (Hons), Ph.D., Grad Dip Bus, PGCert HEHCP York

General Manager Research, Audit and Academic Surgery, Royal Australasian College of Surgeons

Adjunct Associate Professor, University of Adelaide

24 King William St, Kent Town, South Australia 5067, Australia

Email: wendy.babidge@adam.com.au

Aims and Scope: The *International Journal of Technology Assessment in Health Care* has as its specific scope of interest the generation, evaluation, diffusion, and use of health care technology. It addresses the diverse audience of health care providers within medicine, public health, nursing, and the allied health professions; decision makers in government, industry, and health care organizations; and the scholarly disciplines such as ethics, economics, law, history, sociology, psychology, and engineering. The journal aims to fill the needs of those interested in the complexities of interaction between people and technology; technology as a force in social and organizational change; and technology as it is created, produced, applied, and paid for. It examines descriptively and analytically the effects of technology as perceived from the vantage point of different academic disciplines and policy-making organizations and examines methods necessary to conduct studies and evaluations of technology.

The focus of the journal is the international health care community. The experience of different countries in their encounter with health care technology, viewed comparatively, is invaluable to understanding its effects. Further, it is important to establish ties with the scholars, governments, and private institutions concerned with health care technology so that the experiences and learning of the international community in its parts can benefit the whole. The use of technology in health care has created some of the major dilemmas in society today. The journal serves as a forum for the wide range of professionals interested in the assessment of medical technology, its consequences for patients, and its impact on society.

Publishing, Advertising, and Subscription Offices: Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006, U.S.A. (for U.S.A., Canada, and Mexico); or Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK (for U.K. and elsewhere).

2020 Subscription Information: *International Journal of Technology Assessment in Health Care* (ISSN 0266-4623) is

published bimonthly in February, April, June, August, October, and December by Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006; Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK. Annual institutional subscription rates for Volume 36 (2020): Institutions online only US \$654.00, and online only UK and elsewhere £376.00. Individuals online only US \$380.00, and online only UK and elsewhere £214.00. Single part: US \$125.00 in the U.S.A., Canada and Mexico; UK £72.00 and elsewhere. Online only for all institutions. Print editions ceased in 2014. Back volume prices are available upon request. *International Journal of Technology Assessment in Health Care* and other Cambridge journals can be found at <http://journals.cambridge.org>

© Cambridge University Press & Assessment 2022

All rights reserved. No part of this publication may be reproduced, in any form or by any means, electronic or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: <http://www.cambridge.org/rights/permissions.permission.htm>

Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center, <http://www.copyright.com>, email: info@copyright.com.

Postmaster: Send address changes in the U.S.A. and Canada to: *International Journal of Technology Assessment in Health Care*, Journals Department, Cambridge University Press, One Liberty Plaza, Floor 20, New York, NY 10006, U.S.A. Send address changes elsewhere to: *International Journal of Technology Assessment in Health Care*, Cambridge University Press, Journals Fulfillment Department, UPH, Shaftesbury Road, Cambridge CB2 8BS, UK.

Founding Editors: Egon Jonsson and Stanley J. Reiser

Contents

Oral Presentations	s 1
OP01 Convergent Validity Between Discrete Choice Experiment And Other Stated Preference Methods: A Multistudy Comparison	s1
OP02 The Use Of Discrete Choice Experiments For Measuring Patient Preferences In Health Technology Assessment	s1
OP03 Patient Characteristics Affect Their Treatment Choice: A Discrete Choice Experiment With Breast Cancer Patients In Six European Countries.....	s2
OP04 Methodological Challenges Of Assessing An Evolving Technology: The Cochlear Implant For Deaf People.....	s2
OP05 The Role Of Conditional Reimbursement In The Lifecycle Approach	s3
OP06 Percutaneous Transforaminal Endoscopic Discectomy: From Insufficient Evidence To Reimbursement	s3
OP07 Dealing With Uncertainty In Early Health Technology Assessment: An Exploration Of Methods For Decision-Making Under Deep Uncertainty	s3
OP08 Early Access To New Direct-Acting Antiviral: A Journey On Introduction Of Ravidasvir For Hepatitis C Treatment In Malaysia.....	s4
OP10 Outcomes Of Expanded Access To Transcatheter Aortic Valve Implantation In Ontario: A Model-Based Analysis.....	s4
OP11 Differences And Similarities In Past Health Technology Assessments In Benelux Initiative Countries.....	s5
OP12 Post-Launch Evidence Generation Among Health Technology Assessment Bodies In Europe	s5
OP13 EUnetHTA Relative Effectiveness Assessments Of Pharmaceutical And Other Technologies: Procedural Changes Implemented During Joint Action 3	s6
OP14 Involving People With A Lived Experience When Developing A Proposed Health Technology Assessment Of Pelvic Organ Prolapse Treatments	s6
OP15 Improving The Osteoporosis Care Trajectory By Collaboration Between Clinicians, Patients And Health Insurers Within the Appropriate Care Program	s7
OP16 Learning From Engagement With Human Immunodeficiency Virus Community Organizations In The Health Technology Assessment Lifecycle.....	s7
OP17 Robotic Versus Conventional Surgery: An Overview Of Systematic Reviews For Clinical Effectiveness With Quality Assessment Of Current Evidence	s8
OP18 Clinical Effectiveness And Safety Of Implantable Bulking Agents For Fecal Incontinence: A Systematic Review	s8
OP19 Comparative Effectiveness Of Common Treatment Options For Benign Prostatic Hyperplasia: A Systematic Review And Network Meta-Analysis.....	s8
OP20 Is The Quality Of Evidence In Health Technology Assessment Deteriorating Over Time?: A Case Study On Cancer Drugs In Australia	s9
OP21 A Critical Review Of Existing Health Inequality And Health Inequity Frameworks In Evidence Synthesis	s9
OP22 Using Threshold Analysis To Guide Searches For Additional Sources Of Evidence.....	s10
OP24 Impact Of Patient Input On Cancer Drug Funding Recommendations In Canada	s10
OP26 Policy Perspectives Of Health Technology Assessment In Ethiopia.....	s10
OP27 Health Technology Assessment Processes, Characteristics, And Key Differences In High, Middle, And Low-Income Countries Of Asia Pacific Region	s11
OP28 Health Technology Assessment: A Situation Analysis Of Zimbabwe	s11
OP29 Lifecycle Assessment Of Machine Learning-Derived Early Warning System. An Early Economic Evaluation Of An Intraoperative Hypotension Prediction Index.....	s12
OP30 <u>M</u> odel for <u>A</u> ssessing The Value Of <u>AI</u> In Medical Imaging (MAS-AI).....	s12
OP31 Assessment Of AI Supported Health Technologies - How To Move Forward?	s13
OP32 A Multistep Multistakeholder Priority Setting Exercise For Fecal Incontinence	s13
OP33 Expectations, Needs And Challenges Of Setting Up An International Collaboration On Horizon Scanning For Medical Devices.....	s13
OP34 Horizon Scanning A Matter Of Collaboration. A Description Of The Processes Of I-HTS Member Organizations.....	s14
OP35 Suitability Of Preference Methods Across The Medical Product Lifecycle: A Multicriteria Decision Analysis.....	s14
OP36 A Lifecycle Approach In Evaluating Medical Technologies: Insights From The National Institute For Health And Care Excellence Guidance Review Process	s15

OP37 Lifecycle Evaluation Models And Frameworks Used To Assess Medical Devices: A Qualitative Evidence Synthesis	s15
OP38 Managed (Early) Access In England: The 'Ins And Outs'	s16
OP39 The Real-Option Rate Of Return Approach To Inform The Pricing Of Medicines	s16
OP41 Facilitating Dialogue Of Real-World Evidence Use In Health Technology Assessment: Taxonomy Of Question/Data Source Pairings To Support A Registry Of Studies.....	s16
OP42 Increasing Access To Real-World Data To Move From Health Technology Assessment To Health Technology Management	s17
OP43 Conceptual And Methodological Factors Driving The Integration Of Real-World Evidence In Drugs And Technologies Reimbursement Appraisals	s17
OP44 Does The Health Economic Modelling Structure Matter? An External Validation Of Three Approaches Commonly Used In Obesity Modelling.....	s18
OP46 Assessing The Quality Of Pharmacoeconomic Evaluations About Type 2 Diabetes Mellitus Drugs In National Reimbursement Drug List	s18
OP48 Interactions Between Regulatory, Health Technology Assessment And Companies: Multi-Stakeholder Survey On The Current Experiences And Future Landscape Evolution.....	s19
OP49 A Systematic Review Of The Activities Of Early Advice, Early Dialogue, Scientific Advice By HTA Doers.....	s19
OP50 Health Equity Considerations In HTA: A Case Example Of Prenatal Screening.....	s20
OP51 Improving Childhood Cancer Management And Financing In Ghana: Results From Stakeholder Mapping and Analysis.....	s20
OP52 Health Technology Assessment Of Pain-Free Blood Draw Devices In Pediatrics.....	s20
OP54 The Early Detection And Warning System 'SINTESIS-New Technologies': A Horizon Scanning Experience In Spain	s21
OP55 Classification System For Innovative Medicines In The Pipeline: New Or Repurposed?.....	s21
OP56 A Life Cycle Approach To Horizon Scanning Outputs - From Signals To Guidelines	s22
OP57 The Identification Of Technological Innovations To Address The Challenge Of Antimicrobial Resistance Using Horizon Scanning Approaches	s22
OP59 The Tunisian Guidelines For Pharmacoeconomic Analysis: What We Need To Know	s23
OP60 Methodological Guidance And Doctrine Of The French National Authority For Health For Economic Evaluation.....	s23
OP62 Patients' Opinion On Health Technology Assessment Reports: An Analysis Of Brazilian Health Technology Assessment In 2021.....	s23
OP63 Patient and Public Perspectives On The Scottish Medicines Consortium Detailed Advice Document.....	s24
OP64 NICE Listens: Engaging The Public On How To Address Health Inequalities In Health Technology Assessment And Guideline Development.....	s24
OP65 An Overview Of Participatory Approaches, Stakeholders, Methods, Topics and Challenges In Medical Device Development: A Scoping Review.....	s25
OP67 Considerations Of Treatment Novelty In Health Technology Assessment	s25
OP68 Real-World Experience With The National Institute For Health And Care Excellence's Willingness To Accept Less Costly, Less Effective Healthcare Technologies	s26
OP70 Gaps In The Evaluation Of Clinical Decision Support Software (CDSS): Interviews With Australian Policymakers	s26
OP71 PriTec Tool 2: Adaptation For Selection Of Technologies To Be Assessed For Inclusion Into The Health Care System.....	s27
OP72 Software Tools For Systematic Literature Review In Medicine: A Review And Feature Analysis.....	s27
OP73 Tools That Can Aid Adaptive HTA To Ensure Rapid, Efficient, And Pragmatic Priority Setting: A Scoping Review	s27
OP74 Assessing Public Confidence Towards COVID-19 Vaccines Through Social Media Insights Leveraged Using Artificial Intelligence Techniques	s28
OP76 "Thunderbirds Are Go!" Rapid Response HTA Outputs For COVID-19	s28
OP78 Taking A Societal Perspective In Health Technology Assessment: Is Environmental Impact A Special Case?	s29
OP79 Incorporating Environmental Impacts Into Health Technology Assessment: An Examination Of Potential Approaches And Challenges	s29
OP80 'Green Metrics' - Incorporating Environmental Dimensions In Health Technology Assessment.....	s30
OP81 Do Sustainable Healthcare Principles Inform Guidance Development? An Exemplary Case Study In Respiratory Care	s30
OP82 Patient Involvement In Health Technology Assessment.....	s30
OP83 Joining Efforts To Improve Patient Involvement In Health Technology Assessment: The Case Of The RedETS Patient Interest Group	s31
OP84 Cost Consequence Analysis: A Potential Framework To Incorporate Patient Preferences Into Health Technology Assessment And Reimbursement Decisions	s31
OP86 Chatbot-Based Symptom-Checkers: A Systematic Review	s32

OP87 Value From A Multi-stakeholder Perspective: A Framework To Assess Digital Health Solutions For Improving Chronic Disease Management	s32
OP88 Drawing Lines In The Sand: How Do We Define The Scope Of Analysis In HTA And Economic Evaluation?	s33
OP89 The CE-Signal, A New Simplified Health Technology Assessment Method To Determine Whether Interventions Are Cost-Effective	s33
OP90 Optimizing Health Technology Assessment And Appraisal For Orphan Drug Reimbursement: Experiences And Tools For Improvement	s33
OP91 The Current State Of Disease-Specific Registries For The Monitoring Of Expensive Pharmaceuticals In The Netherlands	s34
OP92 Impact Of Real-World Evidence On Health Technology Assessment And National Guidance For Interventional Procedures: A UK Perspective	s34
OP93 Informing Efficient Diagnostic Monitoring Pathways Using Prospective Cohort Data: A Case Study In Neovascular Age-Related Macular Degeneration	s35
OP94 Online Elicitation Of Personal Utility Functions (OPUF): A New Tool For Eliciting EQ-5D-5L Value Sets On The Societal-, Group-, Subgroup-, And Individual-Level	s35
OP95 Examining The Feasibility And Acceptability Of Valuing The Lebanese Version Of The SF-6D Using Standard Gamble	s36
OP96 Patient Reported Outcome Measure-Select App	s36
OP97 Stakeholders' Involvement In Brazilian Health Technology Assessment Incorporation In 2021: A Statistical Description Of Demands To The Brazilian National Committee For Health Technology Incorporation	s37
OP99 Participatory Approaches Used In Research And Development Of Medical Devices: A Comparison Of Focus groups, Interviews And Surveys	s37
OP103 Enhancing Legitimacy And Coherent Value Appraisal Across Interventions In Healthcare And Social Services: Strategy Of The Québec Agency	s38
OP105 Gaps, Challenges And Priorities For Neurodegenerative Disease Research And Health Technology Assessment	s38

Poster Presentations

PP02 Is Glycated Hemoglobin A Valid Surrogate Endpoint To Evaluate The Effectiveness Of Drugs In Diabetes Mellitus Studies?	s39
PP03 Early Assessment Of Video Consultations In Rehabilitation After Hand Injury	s39
PP04 Supporting The Social Integration Of Persons With Brain Injury Using Psychoactive Substances: A Health Technology And Intervention Assessment	s39
PP05 Effect Modifiers In Indirect Treatment Comparisons: Guidance Is Needed To Ensure An Unbiased Identification In Decision-Making	s40
PP06 Clinical Effectiveness Of Fluticasone Furoate Nasal Spray For Perennial Allergic Rhinitis In Children: A Systematic Review And Meta-Analysis	s40
PP07 Improving The Use Of Real-World Evidence In The Development Of NICE Guidance	s41
PP08 Evaluation Of Nutritional Status In Diabetic And Non-Diabetic Chronic Kidney Disease Patients Using A Web Tool	s41
PP09 Use Of Real-World Evidence For Managing Health Technologies Throughout The Life Cycle Of Transcatheter Aortic Valve Interventions	s42
PP10 Impact Of COVID-19 On The Management Of Breast Cancer In Italy: The Perspectives Of Patients And Coordinators	s42
PP11 Impact Of Qualitative Research In The Spanish Network Of Health Technology Assessment	s42
PP12 Challenges In Assessing The Efficacy Of Non-Pharmacological Measures In The Context Of The COVID-19 Pandemic	s43
PP13 Development Of Recommendations And Proposal For A Value-Based Managed Entry Agreement For Italian Setting	s43
PP14 Value-Based Pricing For Advanced Therapy Medicinal Products: Emerging Affordability Solutions	s44
PP15 The National Pricing And Reimbursement Process In China, A 2021 Update	s44
PP16 Machine Learning In The Treatment Of Spinal Deformities: Early Life-cycle Economic Analysis In Australia	s44
PP17 Is the PriTec Tool Useful In The Identification Of Disruptive Healthcare Technologies?	s45
PP18 Horizon Scanning For Clinical Biosimilar Medicines: Informing The Lifecycle Of Health Technology Assessment And Market Access	s45
PP19 Reimbursable Health Apps (DiGA) In Germany: Which Factors Impact The BfArM's Assessment And Directory Listing? – Updated Research	s46
PP20 Effectiveness And Safety Of Autogenic Training As A Treatment For Medical Conditions	s46
PP21 Efficacy And Safety Of Aromatherapy: An Overview Of Systematic Reviews	s47
PP22 A Lifecycle Approach To The Use Of Real-World Evidence In HTA Submissions And Resubmissions: A Decade's Experience	s47
PP23 Lost In Translation? The Differences In The Use Of Real-World Evidence Across Key Markets	s47
PP24 Organizing Outpatient Parenteral Antibiotic Therapy: Lessons from Denmark	s48

PP25 Brazilian Collaborative Network For COVID-19 Modeling: Successful Experience Of Using Real-Time Science To Support Evidence-Based Decision-Making.....	s48
PP26 Cost Utility Of Vaccination Against COVID-19 In Brazil.....	s49
PP27 Reusing And Adapting Health Technology Assessments (HTAs): An Example From The COVID-19 Time.....	s49
PP28 Is My Medicine Suitable For An Outcomes Based Agreement? The Feasibility Conundrum.....	s50
PP32 Assessment Of Preferences For Treatment: A Discrete Choice Experiment Among Italian Patients With Prostate Cancer.....	s50
PP33 Molecular Markers For The Detection Of Clinically Significant Prostate Cancer.....	s51
PP34 Next Generation Sequencing For Informing Lung Cancer Therapy In Europe – Hospital Impact With A Lifecycle Perspective.....	s51
PP35 Defecography (Evacuation Proctography) For The Evaluation Of Pelvic Floor Disorders: A Literature Review.....	s52
PP36 Joint Replacement Under Computer Navigation And Robotic Systems.....	s52
PP37 A Systematic Review Of Machine Learning And Statistical Models For Predicting Coronary Heart Disease In Diabetic Patients.....	s52
PP39 Evidence Generation For Reimbursement Of Digital Health Applications (DiGAs) In Germany.....	s53
PP40 Health Apps To Manage Depression: Can We Separate The Grain From The Chaff? EvalDepApps Project.....	s53
PP41 COVID-19 Modeling To Support Decision Making In Brazil: A Scoping Review.....	s54
PP42 Impact Of The COVID-19 Pandemic On Scottish Medicine Consortium Submission Characteristics, Acceptance Rates, And Time To Advice.....	s54
PP43 Impact Of The COVID-19 Pandemic In The Brazilian National Committee for Health Technology Incorporation (Conitec) Recommendation Process.....	s55
PP45 The Cost-Of-Illness Of Diabetic Macular Edema In Italy.....	s55
PP46 INEAS Guidelines For Pharmacoeconomic Evaluation: Focus On Health-Related Quality of Life Recommendations.....	s55
PP47 Modelling Non-small Cell Lung Cancer Treatment: Predicted and Observed Impact Of Immunotherapy In The Netherlands.....	s56
PP48 A Micro-Costing Study For Circulating Tumor DNA testing In Oncology.....	s56
PP49 Financing The Line Of Care In The First Biochemical Relapse Of Prostate Cancer After [⁶⁸ Ga] PSMA PET-CT.....	s57
PP51 Strengths And Limitations Of Migraine Management Guidelines In The USA and Europe: A Targeted Literature Review.....	s57
PP52 Transcranial Magnetic Stimulation For The Treatment Of Cocaine Addiction: A Systematic Review.....	s58
PP53 Applying The VALIDATE Approach To Frame The Assessment Of Integrated Care Management In Aortic Valve Stenosis.....	s58
PP56 The Use of Computed Tomography for Detecting COVID-19 Pneumonia: Rapid Evidence Review.....	s59
PP57 Collaborating In Times Of COVID: The Launch Of The National Wales COVID-19 Evidence Centre.....	s59
PP58 SARS-CoV-2: A Rapid Review Of The Transmission Risk From Vaccinated Populations.....	s60
PP59 Multidimensional Evaluation Of The Reducer Device In Patients With Refractory Angina.....	s60
PP61 Plugging the Gap of Fetoscopy in Congenital Diaphragmatic Hernia Pregnancies: Value for Money?.....	s60
PP62 Recommendations On Methodologies To Obtain Comparator Efficacy In Health Economic Assessments Of Tumor-Agnostic Drugs.....	s61
PP66 Safety, Effectiveness And Cost-effectiveness Of Scalp Cooling Devices For The Prevention Of Chemotherapy-induced Alopecia.....	s61
PP68 Dexcom G6 [®] Device For Diabetes During Pregnancy.....	s62
PP69 Supporting Decision Making: A Health Technology Assessment Training Proposal for Decision Makers.....	s62
PP70 Enhancing HTA Processes In The Maltese System For Introducing New Medicines.....	s63
PP71 Lessons Learned During Analyses Of Appropriate Hearing Care: Building Bridges Between Patient Organizations, Health Professionals And Insurance Companies.....	s63
PP72 SARS-CoV-2: A Rapid Review On The Effectiveness Of Face Coverings To Reduce Transmission.....	s63
PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis.....	s64
PP76 Database On Evidence-Based Telemedicine In A Hospital Setting.....	s64
PP77 Safety, Effectiveness, And Cost Effectiveness Of Telemedicine In Neurological Diseases.....	s65
PP78 Effectiveness And Safety Of The FreeStyle Libre [®] Glucose Monitoring System For T1DM In Childhood And Adolescence.....	s65

PP79 Use Of Vagus Nerve Stimulation Therapy In Treatment-Resistant Depression	s66
PP81 Barriers To Implementation Of Health Technology Assessment	s66
PP82 First Educational Trainings According To New Health Technology Assessment Guideline For Medicines In Ukraine.....	s66
PP83 Economic Impact Of Missed Vaccinations On The Italian National Health System	s67
PP84 Change Management Of Patient Associations In Italy: From Emergency Response To Organizational Learning	s67
PP85 The Cost-Effectiveness Of The Anti-COVID Vaccination Campaign In The Italian Healthcare Setting	s68
PP88 Bayesian Joint Models For Cost-Effectiveness Analyses Based On Clustered Participant Data, With Implementation In Stan.....	s68
PP89 Stimulating And Assuring Evidence Quality From A Dutch Funders' Perspective – Introducing The ZonMw Reporting Checklist	s69
PP90 Startup And Inclusion Problems In Healthcare Efficiency Studies: A Quantitative And Qualitative Analysis.....	s69
PP91 Developing A Re-assessment Process For Non-medicine Health Technologies In Wales	s69
PP92 Should Missing Data Be Multiply Imputed Prior To Longitudinal Linear Mixed-Model Analyses In Trial-Based Economic Evaluations?	s70
PP93 The Impact Of Using Different EQ-5D Scoring Methods On Cost-Utility Outcomes: A Simulation Study.....	s70
PP94 Exploring The Relationship Between Price And Outcome Of The Health-Economic Assessment In Japan	s71
PP95 Health Professionals' Participation On Health Technology Assessment (HTA) Public Consultation: A Distribution Analysis Of Brazilian HTA In 2021	s71
PP96 Joint Clinical Assessments – Implementation And Lessons For The Next Stage Of EU HTA	s72
PP97 Recommendations For Generating South African Health-Related Quality Of Life Data For Cost-Utility Analyses	s72
PP98 Occupational Therapy For Adult Persons With Cognitive Impairments: A Systematic Overview On Clinical Efficacy	s72
PP100 Improving The Assessment Of Effectiveness For Digital Applications Using The B Statistic: Using WtsWrng As A Case Study.....	s73
PP101 Development Process Of The Economic Guidelines In Tunisia	s73
PP102 Selecting The Sequence Of Diagnostic Tests For Leprosy In Brazil	s74
PP103 Early Health Technology Assessment Of Integrated Care To Increase Employment For Persons With Substance Use Disorder.....	s74
PP107 Scale For Measuring Fatigue In Patients With Parkinson's Disease: Scientific Technical Report	s74
PP108 Multidimensional Analysis Of Peristeen Plus Medical Device.....	s75
PP109 Efficacy And Safety Of High-Intensity Focused Ultrasound In Parkinson's Disease.....	s75
PP110 An External Combined Occipital And Trigeminal Neurostimulation Device For Migraine Treatment	s76
PP111 Reimbursement And Payment Models: A Survey Of Stakeholders' Current Experiences And Future Outlook Within The Dutch Policy Setting	s76
PP112 Reimbursement Decisions for Medical Services in Austria: An Analysis of Influencing Factors for the Hospital Individual Services Catalogue	s77
PP113 Reimbursement Of Oncology Therapies With Limited Clinical Evidence In The Netherlands	s77
PP114 The Influence Of Implicit Factors On The Health Technology Assessment Deliberative Process: A Survey In Five European Countries	s78
PP115 Analysis Of Previous Joint Clinical Assessment And Potential Transferability To Four European Countries: Case Study And Conceptual Approach	s78
PP117 Larger Impact Of An Appropriate Care Program By Involving Healthcare Professionals: A Case Report On Cervical Pre-malignancy.....	s78
PP118 Cyclic Mental Health Technology Assessment with Priority Setting And Involving Stakeholders - A Case Report From The Netherlands	s79
PP119 Results And Lessons Learned From The Cyclic Appropriate Care Program From National Health Care Institute Of The Netherlands	s79
PP120 Fluorescent In Situ Hybridization (FISH) Vs Conventional Cytogenetic (CC) For Detecting High-Risk Genetic Mutations In Multiple Myeloma	s80
PP122 Magnetic Resonance-guided High-intensity Focused Ultrasound For Non-surgical Treatment Of Prostate Cancer, Uterine Fibroids, Adenomyosis And Pain In Bone Metastases	s80
PP123 Fair Drug Pricing: Review Of Literature And Models	s81
PP124 The Importance Of Flexible PPI Approaches: Case Study On Flash Glucose Monitoring	s81
PP125 Economic Evaluation Of Molecular Diagnostics – A Review And Future Directions	s81
PP126 Direct Patient Involvement In HTA In Canada And Brazil: The Patients' Perspectives.....	s82
PP127 Impact Of Brazilian Patient Testimonials On Medical Devices And Public Confidence In The Healthcare Decision-Making.....	s82

PP128 Development And Piloting Of An Online Training Course On Health Technology Assessment For Patients	s83
PP129 Usefulness, Acceptability And Satisfaction Of A Decision Making Tool For Clinical Meso-Management In Type 2 Diabetes Mellitus	s83
PP131 European Market Access Landscape Analysis Of Reimbursement Drivers In Pompe Disease: Results From 26 Payer Interviews	s84
PP132 Disinvestment Initiatives In Health Care: A Scoping Review Of Systematic Reviews	s84
PP134 Health Technology Assessment Life Cycle Approach In Asthma Care	s84
PP140 Economic Evaluation Of Several Vaccination Strategies Against Rotavirus In Spain	s85
PP142 Time-Driven Activity-Based Costing (TDABC) Of Brazilian Public Healthcare System (SUS): Preliminary Results For Osteogenesis Imperfecta (OI)	s85
PP143 International Assessment of the Health Care System in Kazakhstan. A performance analysis	s86
PP145 Improving Patient Expert Involvement In The Lifecycle Of Health Technology Assessments To Build Public Confidence In Decision-Making	s86
PP146 The Use Of Indirect Comparisons For Reimbursement Decision Making In The Netherlands And England.....	s87
PP147 Conditional Reimbursement Of Medicinal Products, A Procedure For Orphan Drugs, Conditionals and Exceptionals.....	s87
PP148 The Impact Of Health Technology Wales Guidance For Autologous Hematopoietic Stem Cell Transplantation: Two Years Post-Publication.....	s87
PP149 A Multidimensional And Multistakeholder Approach: Assessing Ethical, Legal, Organizational, Social or Patient-centered (ELSI+) for Telemedicine In Neurological Diseases.....	s88
PP150 The Role Of Expert Consensus In UK Guidance: Patient Selection For Hydrogel Spacer Use During Prostate Cancer Radiotherapy.....	s88
PP151 VALIDATE Methodology On A Medication-Related Clinical Decision Support System: Holistic Assessment For Optimal Technology Adoption	s89
PP152 The Assessment Of The Price Of A Medicine: The Possible Application Of Cost-Based Pricing Methods	s89
PP153 The Economic And Fiscal Impact Of Public Health Programs For Diabetic Patients In Italy	s90

Poster Debate

PD01 Using ELISA Tests For Monitoring Response To Anti-TNFs In Rheumatoid Arthritis: Findings From A NICE Health Technology Assessment	s90
PD02 A Literature Review Of Treatment Schemes And Effects For Beta Thalassemia In China.....	s91
PD03 Uptake Of Health Technology Assessment In Hospitals: A Scoping Review.....	s91
PD05 Novel Non-Thermal Ablation Technology For The Treatment Of Atrial Fibrillation.....	s91
PD07 Cost-Effectiveness Of Direct Oral Anticoagulants In Chinese Patients With Non-Valvular Atrial Fibrillation	s92
PD08 A Systematic Review Of Reporting Quality Of Economic Evaluations In TCM In NRDL Of China Based On CHEERS.....	s92
PD09 Comparing Long-term Costs Associated With Intraocular Lens Selection And Nd:YAG Laser Capsulotomy In The UK: A Cost-Consequence Analysis.....	s93
PD10 Quality Of Economic Evaluation Of Coronary Stents Based On CHEERS: A Scoping Review.....	s93
PD12 Quality Assessment Of Health Economic Evaluation On Screening Programs From China.....	s93
PD13 Methodologies In Economic Evaluations Of Biomarkers – A Systematic Review	s94
PD14 A New Equitable Biomedical Research And Development Model: Preliminary Findings From A Pilot Study Applying VALIDATE Value Methods.....	s94
PD15 Horizon Scanning To Nominate Subsidy Evaluation Topics For Medical Technologies: Early Experience From Singapore	s95
PD16 Reassessment And Selection Strategy Of Dipeptidyl Peptidase-4 Inhibitors For Ministry Of Health Malaysia Medicine Formulary	s95
PD17 Automating The Impact Reporting Of NICE Guidance	s96
PD19 Machine Learning Modelling For Clinical Trial Design Using The National Institute for Health and Care Research Innovation Observatory's ScanMedicine Database.....	s96
PD20 Real-World Evidence To Support Single Arm Trials Of Oncology Interventions: Necessity or 'NICE' (National Institute for Health and Care Excellence) to Have?	s96
PD21 Data Sources And Real-World Data On Medical Devices In The Brazilian Scenario.....	s97
PD22 Exploratory Analysis of a Brazilian Real-World Open Database Applied to Prostate Cancer.....	s97
PD23 Assessing The Suitability Of Real-World Data For Answering Decision Problems – NICE's Data Suitability Assessment Tool	s98
PD24 Robust Real-World Evidence Generation In Comparative Effects Studies – NICE's Methods Guidance.....	s98

PD25 Use Of Real-World Evidence In The Reimbursement Assessment Of Medical Devices	s99
PD26 Overscreening For Older Women In Cervical And Breast Cancer Screening In Japan	s99
PD28 Cost-Effectiveness Of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres For Unresectable Hepatocellular Carcinoma In Brazil	s99
PD29 Systematic Review With Meta-analysis Of Pharmacokinetic Parameters Of Tyrosine Kinase Inhibitors Used In Chronic Myeloid Leukemia	s100
PD30 Radioactive Seed Localization And Radio-Guided Occult Lesion Localization For Non-Palpable Breast Cancer Surgery: A Meta-Analysis.....	s100
PD32 Cost-Utility Of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres For Chemotherapy-Refractory Metastatic Colorectal Cancer In Brazil	s101
PD33 Development And Validation Of A Machine Learning-Based Prediction Model For COVID-19 Diagnosis Using Patients' Metabolomic Profile Data	s101
PD34 Neuron-specific Biomarkers Associated With Neurological Manifestations In COVID-19: An Evidence Mapping Systematic Review	s102
PD35 Mortality And Risk Factors Associated With Dialysis Patients With COVID-19 In A Brazilian Supplementary Health Service	s102
PD36 Outcomes Of Centenarians Hospitalized Due To COVID-19 In A Private Healthcare System	s103
PD37 High-Dose Vitamin D For The Treatment Of COVID-19.....	s103
PD38 Telehealth Use To Fight The COVID-19 Pandemic In A Brazilian Private Healthcare System.....	s104
PD39 Strategies To Assist People With Disabilities During Health Emergencies, Concerning The COVID-19 – Systematic Review	s104
PD40 Antigen Diagnostic Tests With Self-Collection Of Biological Material For The Diagnosis Of COVID-19.....	s104
PD41 Role Of Artificial Intelligence In Improving Access To COVID-19 Diagnosis During Pandemic	s105
PD42 Diagnosis Of Chronic Diseases During The COVID-19 Pandemic Through Telemedicine	s105
PD43 Estimating Societal Costs Associated With Vision Loss And Delayed Cataract Surgery: The Potential Impact Of The COVID-19 Pandemic.....	s106
PD44 Realistic Review: Theoretical Model For Monitoring And Evaluation (M&E) Of Health Technology Assessment Management.....	s106
PD45 Paying For Digital Health: What Evidence Is Needed?	s106
PD46 Multi-Criteria Decision Analysis In Healthcare: Scientometric And Bibliometric Analysis.....	s107
PD47 Associations Of Orphan Designation And Other Drug Development-Related Factors On Rollout Times And Health-Technology-Assessment Recommendations Of New-Active-Substances	s107
PD48 Does Unmet Need Influence The Scottish Medicines Consortium Health Technology Assessment Decisions For Rare Disease Conditions?	s108
PD49 Burden And Cost Of Anterior Cruciate Ligament Reconstruction And Reimbursement Of Its Treatment In Indonesia: An Observational Study.....	s108
PD50 Value Of Healthcare Journey For Patients With Rare Diseases In The Brazilian Public Healthcare System: Methods And Preliminary Results	s109
PD51 Patient Perspective: A Preliminary Analysis Of The First Year Of The Patient Involvement in CONITEC Meetings.....	s109
PD52 The Role Of Public Consultation In CONITEC Recommendations Between 2012 And 2020: An Introductory Analysis	s110
PD53 Improving Patient Involvement In The National Institute For Health And Care Excellence's Appeals Process	s110
PD54 Burden Of Disease And Risk Factors Among Children Under 5 Years In China From 1990 To 2019.....	s110
PD55 Evidence-Based Practices To Support Well-Being And School Success Of Children And Youth In Out-Of-Home Care	s111
PD56 Conceptual Issues In The Valuation Of Health States In Children.....	s111
PD58 Implementation And Assessment Of A Lung Cancer Screening Pilot Project In Québec Through Multi-Stakeholder Collaboration	s112
PD60 What Are The Opportunities And Challenges To Implementing Value Based Healthcare Pilots In The Brazilian Private Healthcare System?	s112
PD61 What Are The Drivers Of Transitioning From Fee-For-Service To Value-Based Payment Models In The Brazilian Private Healthcare System?	s113
PD63 Impact Of Parallel Submission On The Rollout Time and Health-Technology-Assessment Recommendation Of New-Active-Substances	s113